Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

被引:91
作者
Debin, A
Kravtzoff, R
Santiago, JV
Cazales, L
Sperandio, S
Melber, K
Janowicz, Z
Betbeder, D
Moynier, M
机构
[1] Biovector Therapeut, F-31676 Labege, France
[2] Rhein Biotech GmbH, D-40595 Dusseldorf, Germany
关键词
recombinant proteins; SMBVTM cationic nanoparticles; mucosal and CTL responses;
D O I
10.1016/S0264-410X(02)00191-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
New cationic nanoparticles (SMBV(TM)) were evaluated for use as a nasal vaccine delivery system for two recombinant proteins: HBsAg and P-galactosidase. Each protein was formulated with SMBV(TM) and intranasally administrated to non-anesthetized mice, In each model, the formulated protein induced high levels of specific serum IgG antibodies and cytotoxic T lymphocyte (CTL) responses. Moreover, specific IgA antibodies were found in nasal as well as in vaginal washes of intranasally immunized mice with the protein associated with SMBV(TM). In contrast, no IgG or I-A antibodies and no CTL were detected in mice immunized with free protein, The detection of a CTL response and an increase in both IgG1 and IgG-2a antibodies in serum suggest that SMBV(TM) amplifies both Th1 and Th2 responses without modifying the Th1/Th2 profile of the immune response induced by the natural protein. These data demonstrate the high potential of SMBV(TM) for use as a nasal delivery system for sub-unit vaccines. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2752 / 2763
页数:12
相关论文
共 61 条
[1]   Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1 [J].
Alfsen, A ;
Iniguez, P ;
Bouguyon, E ;
Bomsel, M .
JOURNAL OF IMMUNOLOGY, 2001, 166 (10) :6257-6265
[2]   IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection [J].
Arulanandam, BP ;
Raeder, RH ;
Nedrud, JG ;
Bucher, DJ ;
Le, JH ;
Metzger, DW .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :226-231
[3]   Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses [J].
Baca-Estrada, ME ;
Foldvari, M ;
Snider, M ;
Harding, K ;
Kournikakis, B ;
Babiuk, LA ;
Griebel, P .
VACCINE, 2000, 18 (21) :2203-2211
[4]   Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration [J].
Baldridge, JR ;
Yorgensen, Y ;
Ward, JR ;
Ulrich, JT .
VACCINE, 2000, 18 (22) :2416-2425
[5]   Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV [J].
Becquart, P ;
Hocini, H ;
Lévy, M ;
Sépou, A ;
Kazatchkine, MD ;
Bélec, L .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :532-539
[6]   Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine [J].
Belshe, RB ;
Gruber, WC ;
Mendelman, PM ;
Mehta, HB ;
Mahmood, K ;
Reisinger, K ;
Treanor, J ;
Zangwill, Z ;
Hayden, FG ;
Bernstein, DI ;
Kotloff, K ;
King, J ;
Piedra, PA ;
Block, SL ;
Yan, LH ;
Wolff, M .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1133-1137
[7]   Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice [J].
Blanchard, TG ;
Czinn, SJ ;
Redline, RW ;
Sigmund, N ;
Harriman, G ;
Nedrud, JG .
CELLULAR IMMUNOLOGY, 1999, 191 (01) :74-80
[8]   Interleukin 12 and innate molecules for enhanced mucosal immunity [J].
Boyaka, PN ;
Lillard, JW ;
McGhee, J .
IMMUNOLOGIC RESEARCH, 1999, 20 (03) :207-217
[9]   Mucosal immunology of the upper airways: An overview [J].
Brandtzaeg, P ;
Jahnsen, FL ;
Farstad, IN ;
Haraldsen, G .
IMMUNOLOGIC DISEASES OF THE EAR, 1997, 830 :1-18
[10]   IgA deficiency [J].
Burrows, PD ;
Cooper, MD .
ADVANCES IN IMMUNOLOGY, VOL 65, 1997, 65 :245-276